Randomized Trial of 2 Schedules of Meningococcal B Vaccine in Adolescents and Young Adults, Canada1
| Autor: | Caroline Quach, Donna MacKinnon-Cameron, Erin L Brown, Kim Marty, Jill Mutch, Joanne M. Langley, Lingyun Ye, Joenel Alcantara, Brian J. Ward, Soren Gantt, Scott A. Halperin, David W. Scheifele, Shelly A. McNeil, Julie A. Bettinger |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Microbiology (medical)
Pediatrics medicine.medical_specialty Epidemiology business.industry 030231 tropical medicine Outbreak Meningococcal vaccine Meningococcal disease medicine.disease 3. Good health law.invention Vaccination 03 medical and health sciences 0302 clinical medicine Infectious Diseases Immunization Randomized controlled trial Tolerability law medicine 030212 general & internal medicine Adverse effect business |
| Zdroj: | Emerging Infectious Diseases. 26:454-462 |
| ISSN: | 1080-6059 1080-6040 |
| Popis: | Emergency vaccination programs often are needed to control outbreaks of meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) on college campuses. Such campaigns expend multiple campus and public health resources. We conducted a randomized, controlled, multicenter, observer-blinded trial comparing immunogenicity and tolerability of an accelerated vaccine schedule of 0 and 21 days to a longer interval of 0 and 60 days for 4-component MenB vaccine (MenB-4C) in students 17-25 years of age. At day 21 after the first MenB-4C dose, we observed protective human serum bactericidal titers >4 to MenB strains 5/99, H44/76, and NZ 98/254 in 98%-100% of participants. Geometric mean titers increased >22-fold over baseline. At day 180, >95% of participants sustained protective titers regardless of their vaccine schedule. The most common adverse event was injection site pain. An accelerated MenB-4C immunization schedule could be considered for rapid control of campus outbreaks. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|